[go: up one dir, main page]

MX2020013039A - DERIVED FROM BICYCLIC HETEROAROMATIC RING. - Google Patents

DERIVED FROM BICYCLIC HETEROAROMATIC RING.

Info

Publication number
MX2020013039A
MX2020013039A MX2020013039A MX2020013039A MX2020013039A MX 2020013039 A MX2020013039 A MX 2020013039A MX 2020013039 A MX2020013039 A MX 2020013039A MX 2020013039 A MX2020013039 A MX 2020013039A MX 2020013039 A MX2020013039 A MX 2020013039A
Authority
MX
Mexico
Prior art keywords
derived
heteroaromatic ring
bicyclic heteroaromatic
compound
rhinovirus
Prior art date
Application number
MX2020013039A
Other languages
Spanish (es)
Inventor
Masahiko Kinebuchi
Takekazu Kondou
Koji Ochiai
Yosuke NISHIGAYA
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of MX2020013039A publication Critical patent/MX2020013039A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Proporcionar un compuesto que tiene una acción antiviral sobre un virus perteneciente al género picornavirus, específicamente, un rinovirus. Se proporciona un compuesto representado por la fórmula general (1), una sal farmacéuticamente aceptable del mismo, o un hidrato del mismo.To provide a compound having an antiviral action on a virus belonging to the picornavirus genus, specifically, a rhinovirus. A compound represented by the general formula (1), a pharmaceutically acceptable salt thereof, or a hydrate thereof is provided.

MX2020013039A 2018-08-21 2019-08-20 DERIVED FROM BICYCLIC HETEROAROMATIC RING. MX2020013039A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018154411 2018-08-21
PCT/JP2019/032335 WO2020040104A1 (en) 2018-08-21 2019-08-20 Bicyclic heteroaromatic ring derivative

Publications (1)

Publication Number Publication Date
MX2020013039A true MX2020013039A (en) 2021-02-26

Family

ID=69593150

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013039A MX2020013039A (en) 2018-08-21 2019-08-20 DERIVED FROM BICYCLIC HETEROAROMATIC RING.

Country Status (19)

Country Link
US (1) US11952387B2 (en)
EP (1) EP3842439A4 (en)
JP (1) JP7309725B2 (en)
KR (1) KR20210046649A (en)
CN (2) CN112752761B (en)
AU (1) AU2019324089B2 (en)
BR (1) BR112021002515A2 (en)
CA (1) CA3104054A1 (en)
CL (1) CL2020003116A1 (en)
CO (1) CO2021000512A2 (en)
IL (1) IL278885A (en)
MX (1) MX2020013039A (en)
MY (1) MY200452A (en)
PH (1) PH12020551991A1 (en)
SA (1) SA520420914B1 (en)
SG (1) SG11202012616RA (en)
TW (1) TWI811428B (en)
WO (1) WO2020040104A1 (en)
ZA (1) ZA202101146B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024231436A1 (en) * 2023-05-11 2024-11-14 Arxada Ag Hydrogenation of cyclic ketones

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX3654E (en) 1975-08-28 1981-04-14 Lilly Co Eli PROCEDURE FOR PREPARING SULFONYLBENCIMIDAZOLE COMPOUNDS
JPH0649066B2 (en) * 1985-02-14 1994-06-29 積水化学工業株式会社 Medical adhesive sheet or tape
FR2687574B1 (en) * 1992-02-25 1995-05-05 Rhone Poulenc Rorer Sa NEW THERAPEUTIC APPLICATION OF PYRIDYLPYRROLOTHIAZOLE CARBOXAMIDE DERIVATIVES.
US5349068A (en) 1992-04-15 1994-09-20 Sterling Winthrop Inc. 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
JPH07188017A (en) 1993-09-30 1995-07-25 Souyaku Gijutsu Kenkyusho:Kk Antiviral agent containing thiadiazole derivative
US5453433A (en) 1994-05-13 1995-09-26 Sterling Winthrop Inc. Thiadiazoles and antipicornaviral compositions
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
JPH11106340A (en) * 1997-10-02 1999-04-20 Sumitomo Pharmaceut Co Ltd STAT6 activation inhibitor
US6258831B1 (en) 1999-03-31 2001-07-10 The Procter & Gamble Company Viral treatment
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0321003D0 (en) * 2003-09-09 2003-10-08 Angeletti P Ist Richerche Bio Compounds, compositions and uses
US7229480B2 (en) 2004-02-13 2007-06-12 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
SE0402735D0 (en) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
WO2007129044A1 (en) 2006-05-03 2007-11-15 Astrazeneca Ab Thiazole derivatives and their use as anti-tumour agents
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
CN101878219B (en) * 2007-09-27 2014-04-02 西班牙国家癌症研究中心 Imidazolothiadiazoles for use as protein kinase inhibitors
JP2011529456A (en) 2008-07-29 2011-12-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Imidazothiadiazole derivatives
CA2735875A1 (en) * 2008-09-03 2010-03-11 Boehringer Ingelheim International Gmbh Use of quinazoline derivatives for the treatment of viral diseases
CA2987743A1 (en) 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Purine derivatives and their use as immunosuppressive agents
PL2414369T3 (en) 2009-04-02 2016-04-29 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Imidazo[2,1-b][1,3,4]thiadiazole derivatives
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
GB201115665D0 (en) 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
US9309236B2 (en) 2011-10-05 2016-04-12 The Board Of Trustees Of The Leland Stanford Junior University PI-kinase inhibitors with broad spectrum anti-infective activity
CA2875964C (en) 2012-06-07 2018-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
EP2920177A1 (en) 2012-11-19 2015-09-23 Novartis AG Compounds and compositions for the treatment of parasitic diseases
AP2015008552A0 (en) 2012-12-20 2015-06-30 Univ Leuven Kath Therapeutically active pyrazolo-pyrimidine derivatives
KR20160013028A (en) 2013-05-30 2016-02-03 플렉시콘, 인코퍼레이티드 Compounds for kinase modulation, and indications therefor
ES2954126T3 (en) 2014-01-22 2023-11-20 Curovir Ab Pyrazolo[1,5-a]pyrimidine-7-amine derivatives useful in therapy
JP6678599B2 (en) 2014-06-13 2020-04-08 ユニバーシティー オブ ロチェスター Small molecule efflux pump inhibitor
GB201410817D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D Therapeutic agents
GB201410815D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201410816D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
WO2016145032A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
CA2989722C (en) 2015-06-24 2023-09-19 Jacob Westman Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
EP3118198A1 (en) 2015-07-13 2017-01-18 MMV Medicines for Malaria Venture Anti-malarial agents
WO2017044889A1 (en) 2015-09-10 2017-03-16 The Regents Of The University Of California Lrh-1 modulators
WO2017053192A1 (en) 2015-09-21 2017-03-30 The Board Of Regents Of The University Of Texas System Biomarkers of response to hif-2-alpha inhibition in cancer and methods for the use thereof
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201517264D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201521767D0 (en) 2015-12-10 2016-01-27 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D Therapeutic agents
EP3419980B1 (en) 2016-02-26 2025-01-01 The Board of Trustees of the Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
WO2018022868A1 (en) 2016-07-27 2018-02-01 Lowe Henry C Pi 4-kinase inhibitor as a therapeutic for viral hepatitis, cancer, malaria. autoimmune disorders and inflammation, and a radiosensitizer and immunosuppressant

Also Published As

Publication number Publication date
WO2020040104A1 (en) 2020-02-27
MY200452A (en) 2023-12-27
EP3842439A4 (en) 2022-04-27
CN118084937A (en) 2024-05-28
US20220332730A1 (en) 2022-10-20
US11952387B2 (en) 2024-04-09
JPWO2020040104A1 (en) 2021-08-12
CN112752761A (en) 2021-05-04
ZA202101146B (en) 2022-07-27
EP3842439A1 (en) 2021-06-30
BR112021002515A2 (en) 2021-07-27
PH12020551991A1 (en) 2021-08-02
SG11202012616RA (en) 2021-02-25
AU2019324089B2 (en) 2024-06-13
TWI811428B (en) 2023-08-11
JP7309725B2 (en) 2023-07-18
SA520420914B1 (en) 2023-12-25
KR20210046649A (en) 2021-04-28
IL278885A (en) 2021-01-31
AU2019324089A1 (en) 2020-12-10
CL2020003116A1 (en) 2021-04-16
CO2021000512A2 (en) 2021-01-29
CA3104054A1 (en) 2020-02-27
TW202021971A (en) 2020-06-16
CN112752761B (en) 2024-03-29

Similar Documents

Publication Publication Date Title
CL2022001529A1 (en) New methylquinazolinone derivatives
CO2021008681A2 (en) 15-pgdh inhibitor
AR110400A1 (en) AMINO-TRIAZOLOPIRIDINE COMPOUNDS AND THEIR USE IN CANCER TREATMENT
CO2020014586A2 (en) Compounds
CO2023015419A2 (en) Ring modified short proline peptide compound and use thereof
FI4219508T3 (en) Substituted polycyclic pyridone derivative and prodrug thereof
UY35362A (en) THERAPEUTIC COMPOUNDS
JOP20180123A1 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
MX2017015277A (en) PIRIDO DERIVATIVE [3,4-D] PIRIMIDINE AND PHARMACEUTICALLY ACCEPTABLE SALT OF THIS.
EA202190602A3 (en) 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR TREATMENT OF DISEASES CAUSED BY RNA VIRUS
ECSP19030134A (en) PYRIDINE COMPOUND
MX2018009459A (en) Sulfonamide derivative and pharmaceutical composition containing same.
CL2008003431A1 (en) 2 ', 4' substituted nucleoside derived compounds; process of preparation of said compounds; pharmaceutical composition comprising them; its method of preparation; and its use for the treatment and / or prevention of any condition resulting from an infection by hiv, hiv or hiv.
ES2572001T3 (en) Derived from antiviral bisfuran as an HIV protease inhibitor and intermediates thereof
CL2011002494A1 (en) Compounds derived from 7-aza-di-spiro- [3.0.4.1] -decan-8-carboxamide; pharmaceutical composition comprising them; and use for the treatment of a disorder associated with the hepatitis c virus (hcv) and the human immunodeficiency virus (hiv).
ECSP099601A (en) SERINA PROTEASE INHIBITORS
PH12017501598A1 (en) �-D-2`-DEOXY-2`a-FLUORO-2`-�-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
AR117920A1 (en) HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS
MX2017012396A (en) 9-membered fused ring derivative.
MX389537B (en) PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND ITS PHARMACEUTICALLY ACCEPTABLE SALT.
AR101255A1 (en) ISOINDOLINONE DERIVATIVES
CO2024003094A2 (en) Imidazocyclic compound and application thereof
DOP2018000134A (en) 1,3,4-TIADIAZOL COMPOUNDS AND THEIR USE IN CANCER TREATMENT
MX2020013039A (en) DERIVED FROM BICYCLIC HETEROAROMATIC RING.
MX2023015440A (en) Sulfoximine compound and use thereof.